# Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain

> **NCT02262676** · — · COMPLETED · sponsor: **Bayer** · enrollment: 2251 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)

## Key facts

- **NCT ID:** NCT02262676
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-02
- **Final completion:** 2015-05
- **Target enrollment:** 2251 (ACTUAL)
- **Last updated:** 2017-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02262676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02262676, "Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02262676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*